Exhibit 99.1


                   Revised Telephone Number for Listening to
                ARIAD's Analyst Conference Call on June 15, 2004


   CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 9, 2004--ARIAD Pharmaceuticals, Inc.
(Nasdaq: ARIA) today announced that the telephone number for U.S. investors
wishing to listen to the upcoming analyst conference call to be hosted by the
Company on June 15, 2004 has been revised. The revised telephone number is
888-482-0024. All other telephone numbers, as well as the pass code numbers, in
today's earlier press release announcing the analyst conference call remain
unchanged.
   ARIAD is engaged in the discovery and development of breakthrough medicines
to treat cancer by regulating cell signaling with small molecules. The Company
is developing a comprehensive approach to patients with cancer that addresses
the greatest medical need - aggressive and advanced-stage cancers for which
current treatments are inadequate. ARIAD also has an exclusive license to
pioneering technology and patents related to certain NF-(kappa)B treatment
methods, and the discovery and development of drugs to regulate NF-(kappa)B
cell-signaling activity, which may be useful in treating certain diseases.
   Additional information about ARIAD can be found on the web at
http://www.ariad.com.

   Some of the matters discussed herein are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are identified by the use of words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan," "believe," and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and uncertainties that
may cause actual results, outcome of events, timing and performance to differ
materially from those expressed or implied by such forward-looking statements.
These risks include, but are not limited to, risks and uncertainties regarding
the Company's ability to conduct preclinical and clinical studies of its product
candidates, risks and uncertainties that clinical trial results at any phase of
development may be adverse or may not be predictive of future results or lead to
regulatory approval of any of the Company's product candidates, and risks and
uncertainties relating to regulatory oversight, intellectual property claims,
the timing, scope, cost and outcome of legal proceedings, future capital needs,
key employees, dependence on the Company's collaborators and manufacturers,
markets, economic conditions, products, services, prices, reimbursement rates,
competition and other risks detailed in the Company's public filings with the
Securities and Exchange Commission, including ARIAD's Annual Report on Form 10-K
for the fiscal year ended December 31, 2003. The information contained in this
document is believed to be current as of the date of original issue. The Company
does not intend to update any of the forward-looking statements after the date
of this document to conform these statements to actual results or to changes in
the Company's expectations, except as required by law.


    CONTACT: ARIAD Pharmaceuticals, Inc.
             Tom Pearson, 610-407-9260
             or
             Kathy Lawton, 617-621-2345